Programmed cell death: the pathways to severe COVID-19?

por Bader, Stefanie M., Cooney, James P., Pellegrini, Marc, Doerflinger, Marcel
Publicado 2022

Venetoclax, alone and in combination with the BH3 mimetic S63845, depletes HIV-1 latently infected cells and delays rebound in humanized mice

por Arandjelovic, Philip, Kim, Youry, Cooney, James P., Preston, Simon P., Doerflinger, Marcel, McMahon, James H., Garner, Sarah E., Zerbato, Jennifer M., Roche, Michael, Tumpach, Carolin, Ong, Jesslyn, Sheerin, Dylan, Smyth, Gordon K., Anderson, Jenny L., Allison, Cody C., Lewin, Sharon R., Pellegrini, Marc
Publicado 2023

SARS-CoV-2 mouse adaptation selects virulence mutations that cause TNF-driven age-dependent severe disease with human correlates

por Bader, Stefanie M., Cooney, James P., Sheerin, Dylan, Taiaroa, George, Harty, Leigh, Davidson, Kathryn C., Mackiewicz, Liana, Dayton, Merle, Wilcox, Stephen, Whitehead, Lachlan, Rogers, Kelly L., Georgy, Smitha Rose, Coussens, Anna K., Grimley, Samantha L., Corbin, Vincent, Pitt, Miranda, Coin, Lachlan, Pickering, Raelene, Thomas, Merlin, Allison, Cody C., McAuley, Julie, Purcell, Damian F. J., Doerflinger, Marcel, Pellegrini, Marc
Publicado 2023

Insights Into Drug Repurposing, as Well as Specificity and Compound Properties of Piperidine-Based SARS-CoV-2 PLpro Inhibitors

por Calleja, Dale J., Kuchel, Nathan, Lu, Bernadine G. C., Birkinshaw, Richard W., Klemm, Theresa, Doerflinger, Marcel, Cooney, James P., Mackiewicz, Liana, Au, Amanda E., Yap, Yu Q., Blackmore, Timothy R, Katneni, Kasiram, Crighton, Elly, Newman, Janet, Jarman, Kate E., Call, Melissa J., Lechtenberg, Bernhard C., Czabotar, Peter E., Pellegrini, Marc, Charman, Susan A., Lowes, Kym N., Mitchell, Jeffrey P., Nachbur, Ueli, Lessene, Guillaume, Komander, David
Publicado 2022

Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2

por Wines, Bruce D., Kurtovic, Liriye, Trist, Halina M., Esparon, Sandra, Lopez, Ester, Chappin, Klasina, Chan, Li-Jin, Mordant, Francesca L., Lee, Wen Shi, Gherardin, Nicholas A., Patel, Sheila K., Hartley, Gemma E., Pymm, Phillip, Cooney, James P., Beeson, James G., Godfrey, Dale I., Burrell, Louise M., van Zelm, Menno C., Wheatley, Adam K., Chung, Amy W., Tham, Wai-Hong, Subbarao, Kanta, Kent, Stephen J., Hogarth, P. Mark
Publicado 2022

Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2

por Pymm, Phillip, Redmond, Samuel J., Dolezal, Olan, Mordant, Francesca, Lopez, Ester, Cooney, James P., Davidson, Kathryn C., Haycroft, Ebene R., Tan, Chee Wah, Seneviratna, Rebecca, Grimley, Samantha L., Purcell, Damian F.J., Kent, Stephen J., Wheatley, Adam K., Wang, Lin-Fa, Leis, Andrew, Glukhova, Alisa, Pellegrini, Marc, Chung, Amy W., Subbarao, Kanta, Uldrich, Adam P., Tham, Wai-Hong, Godfrey, Dale I., Gherardin, Nicholas A.
Publicado 2022

Corrigendum: Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2

por Wines, Bruce D., Kurtovic, Liriye, Trist, Halina M., Esparon, Sandra, Lopez, Ester, Chappin, Klasina, Chan, Li-Jin, Mordant, Francesca L., Lee, Wen Shi, Gherardin, Nicholas A., Patel, Sheila K., Hartley, Gemma E., Pymm, Phillip, Cooney, James P., Beeson, James G., Godfrey, Dale I., Burrell, Louise M., van Zelm, Menno C., Wheatley, Adam K., Chung, Amy W., Tham, Wai-Hong, Subbarao, Kanta, Kent, Stephen J., Hogarth, P. Mark
Publicado 2023

Mechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2

por Klemm, Theresa, Ebert, Gregor, Calleja, Dale J, Allison, Cody C, Richardson, Lachlan W, Bernardini, Jonathan P, Lu, Bernadine GC, Kuchel, Nathan W, Grohmann, Christoph, Shibata, Yuri, Gan, Zhong Yan, Cooney, James P, Doerflinger, Marcel, Au, Amanda E, Blackmore, Timothy R, van der Heden van Noort, Gerbrand J, Geurink, Paul P, Ovaa, Huib, Newman, Janet, Riboldi‐Tunnicliffe, Alan, Czabotar, Peter E, Mitchell, Jeffrey P, Feltham, Rebecca, Lechtenberg, Bernhard C, Lowes, Kym N, Dewson, Grant, Pellegrini, Marc, Lessene, Guillaume, Komander, David
Publicado 2020

Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice

por Pymm, Phillip, Adair, Amy, Chan, Li-Jin, Cooney, James P., Mordant, Francesca L., Allison, Cody C., Lopez, Ester, Haycroft, Ebene R., O’Neill, Matthew T., Tan, Li Lynn, Dietrich, Melanie H., Drew, Damien, Doerflinger, Marcel, Dengler, Michael A., Scott, Nichollas E., Wheatley, Adam K., Gherardin, Nicholas A., Venugopal, Hariprasad, Cromer, Deborah, Davenport, Miles P., Pickering, Raelene, Godfrey, Dale I., Purcell, Damian F. J., Kent, Stephen J., Chung, Amy W., Subbarao, Kanta, Pellegrini, Marc, Glukhova, Alisa, Tham, Wai-Hong
Publicado 2021

Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain

por Wheatley, Adam K., Pymm, Phillip, Esterbauer, Robyn, Dietrich, Melanie H., Lee, Wen Shi, Drew, Damien, Kelly, Hannah G., Chan, Li-Jin, Mordant, Francesca L., Black, Katrina A., Adair, Amy, Tan, Hyon-Xhi, Juno, Jennifer A., Wragg, Kathleen M., Amarasena, Thakshila, Lopez, Ester, Selva, Kevin J., Haycroft, Ebene R., Cooney, James P., Venugopal, Hariprasad, Tan, Li Lynn, O Neill, Matthew T., Allison, Cody C., Cromer, Deborah, Davenport, Miles P., Bowen, Richard A., Chung, Amy W., Pellegrini, Marc, Liddament, Mark T., Glukhova, Alisa, Subbarao, Kanta, Kent, Stephen J., Tham, Wai-Hong
Publicado 2021

Interferon-γ primes macrophages for pathogen ligand-induced killing via a caspase-8 and mitochondrial cell death pathway

por Simpson, Daniel S., Pang, Jiyi, Weir, Ashley, Kong, Isabella Y., Fritsch, Melanie, Rashidi, Maryam, Cooney, James P., Davidson, Kathryn C., Speir, Mary, Djajawi, Tirta M., Hughes, Sebastian, Mackiewicz, Liana, Dayton, Merle, Anderton, Holly, Doerflinger, Marcel, Deng, Yexuan, Huang, Allan Shuai, Conos, Stephanie A., Tye, Hazel, Chow, Seong H., Rahman, Arfatur, Norton, Raymond S., Naderer, Thomas, Nicholson, Sandra E., Burgio, Gaetan, Man, Si Ming, Groom, Joanna R., Herold, Marco J., Hawkins, Edwin D., Lawlor, Kate E., Strasser, Andreas, Silke, John, Pellegrini, Marc, Kashkar, Hamid, Feltham, Rebecca, Vince, James E.
Publicado 2022

Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine

por Deliyannis, Georgia, Gherardin, Nicholas A., Wong, Chinn Yi, Grimley, Samantha L., Cooney, James P., Redmond, Samuel J., Ellenberg, Paula, Davidson, Kathryn C., Mordant, Francesca L., Smith, Tim, Gillard, Marianne, Lopez, Ester, McAuley, Julie, Tan, Chee Wah, Wang, Jing J., Zeng, Weiguang, Littlejohn, Mason, Zhou, Runhong, Fuk-Woo Chan, Jasper, Chen, Zhi-wei, Hartwig, Airn E., Bowen, Richard, Mackenzie, Jason M., Vincan, Elizabeth, Torresi, Joseph, Kedzierska, Katherine, Pouton, Colin W., Gordon, Tom P., Wang, Lin-fa, Kent, Stephen J., Wheatley, Adam K., Lewin, Sharon R., Subbarao, Kanta, Chung, Amy W., Pellegrini, Marc, Munro, Trent, Nolan, Terry, Rockman, Steven, Jackson, David C., Purcell, Damian F.J., Godfrey, Dale I.
Publicado 2023